CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

Percutaneous coronary intervention reduces mortality in myocardial infarction patients with comorbidities: Implications for elderly patients with diabetes or kidney disease Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study Cardiac Troponin Composition Characterization after Non ST-Elevation Myocardial Infarction: Relation with Culprit Artery, Ischemic Time Window, and Severity of Injury Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Frequency of nonsystem delays in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention and implications for door-to-balloon time reporting (from the American Heart Association Mission: Lifeline program) Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment The EARLY Randomized Trial Application of High-Sensitivity Troponin in Suspected Myocardial Infarction Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)

Expert Opinion2021 Feb 16;105499.

JOURNAL:Pharmacol Res. Article Link

OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

M Banach, PE Penson, ACS EuroPath Central & South European Countries Project et al. Keywords: PCSK9 inhibitors; combination therapy; effectiveness; ezetimibe; safety; statins

Full Text PDF